The American Journal of Medicine
Volume 123, Issue 3 , Pages 267-274 , March 2010

Higher Incidence of Mild Cognitive Impairment in Familial Hypercholesterolemia

  • Daniel Zambón, MD, PhD

      Affiliations

    • Unitat de Lípids, Institut d'Investigacions Biomédiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Melibea Quintana, MS

      Affiliations

    • Unitat de Lípids, Institut d'Investigacions Biomédiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Pedro Mata, MD, PhD

      Affiliations

    • Servei d'Endocrinologia i Nutrició, Institut d'Investigacions Biomédiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Rodrigo Alonso, MD, PhD

      Affiliations

    • Servei d'Endocrinologia i Nutrició, Institut d'Investigacions Biomédiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Jaume Benavent, MD

      Affiliations

    • Consorci d'Atenció Primària de Salut de l'Eixample, Barcelona, Spain
    • ,
  • Felix Cruz-Sánchez, MD, PhD

      Affiliations

    • Universitat Internacional de Catalunya, Barcelona, Spain
    • ,
  • Jordi Gich, MS

      Affiliations

    • Unitat de Lípids, Institut d'Investigacions Biomédiques August Pi Sunyer, Hospital Clinic, Barcelona, Spain
    • ,
  • Miguel Pocoví, MD, PhD

      Affiliations

    • Servet University Hospital and Department of Biochemistry, Universidad de Zaragoza, Zaragoza, Spain
    • ,
  • Fernando Civeira, MD, PhD

      Affiliations

    • Servet University Hospital and Department of Biochemistry, Universidad de Zaragoza, Zaragoza, Spain
    • ,
  • Sebastian Capurro, MD

      Affiliations

    • Centre de Diagnòstic per l'Imatge, Hospital Clinic, Barcelona, Spain
    • ,
  • David Bachman, MD

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston
    • ,
  • Kumar Sambamurti, PhD

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston
    • ,
  • Joyce Nicholas, PhD

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston
    • ,
  • Miguel A. Pappolla, MD, PhD

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston
    • Corresponding Author InformationReprint requests should be addressed to Miguel A. Pappolla, MD, PhD, Josephine T. Morse, Professor of Neurology, Medical University of South Carolina-Neurosciences, 173 Ashley Ave 403 BSB, Charleston, SC 29425

References 

  1. Masters CL, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006;129:2823–2839
  2. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308
  3. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890
  4. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121–1129
  5. Pappolla MA, Smith MA, Bryant-Thomas T, et al. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic Biol Med. 2002;33:173–181
  6. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321–331
  7. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890–899
  8. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460–6464
  9. Sparks DL, Martin TA, Gross DR, Hunsaker JC. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsc Res Tech. 2000;50:287–290
  10. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61:199–205
  11. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease—epidemiological evidence. Acta Neurol Scand Suppl. 2006;185:50–57
  12. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men (The Honolulu-Asia aging study). Arterioscler Thromb Vasc Biol. 2000;20:2255–2260
  13. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14–20
  14. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–281
  15. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149–155
  16. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19 Pt 2):1795–1802Epub 2008 Jan 16
  17. Newschaffer CJ, Bush TL, Hale WE. Aging and total cholesterol levels: cohort, period, and survivorship effects. Am J Epidemiol. 1992;136:23–34
  18. Zlokovic BV, Yamada S, Holtzman D, et al. Clearance of amyloid beta-peptide from brain: transport or metabolism?. Nat Med. 2000;6:718
  19. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:55–68
  20. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis. 2005;180:155–160
  21. Junyent M, Gilabert R, Zambon D, et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol. 2005;25:2203–2208
  22. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med. 2004;4:67–74
  23. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39:27–38
  24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–296
  25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  26. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158–1159
  27. Otfried Spreen ES. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. New York: Oxford University Press; 1998;
  28. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006;367:1262–1270
  29. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure (Report of the MCI Working Group of the European Consortium on Alzheimer's Disease). J Neurol Neurosurg Psychiatry. 2006;77:714–718
  30. Canevari L, Clark JB. Alzheimer's disease and cholesterol: the fat connection. Neurochem Res. 2007;32:739–750
  31. Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751–756
  32. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2007;64:103–107
  33. Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57:808–813
  34. Cao D, Fukuchi K, Wan H, et al. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging. 2006;27:1632–1643

 Funding: National Institute on Aging (US) AG-022103, AG-10483; Alzheimer's Association Zenith award; the Spanish Ministry of Health (RT/C03-01 and RT/G03-181); the Familial Hypercolesterolemia Foundation of Spain and the Fundació Privada Catalana de Nutrició i Lípids, Barcelona, Spain.

 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00817-1

doi: 10.1016/j.amjmed.2009.08.015

The American Journal of Medicine
Volume 123, Issue 3 , Pages 267-274 , March 2010

Article Tools